JB/CALL/MODERNA/110/0.0166/20.09.24 | Real-time Bid/Ask 08:30:25 2024-05-13 EDT | ||
| 0.29 CHF / 0.3 CHF | -7.81% |
|
| Current month | +18.52% | ||
| 1 month | +28.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.32 | -5.88% | 0 |
| 24-05-08 | 0.34 | +6.25% | 0 |
| 24-05-06 | 0.32 | -13.51% | 0 |
| 24-05-03 | 0.37 | +12.12% | 0 |
Delayed Quote Swiss Exchange
Last update May 10, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRXEJB | |
| ISIN | CH1280667127 |
| Date issued | 2023-08-17 |
| Strike | 110 $ |
| Maturity | 2024-09-20 (130 Days) |
| Parity | 60 : 1 |
| Emission price | 0.3 CHF |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.47 CHF |
|---|---|
| Lowest since issue | 0.09 CHF |
| Spread | 0.01 CHF |
| Spread % | 3.33% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- MRXEJB Warrant
